FeesSafety
Pluang+

Valour's assets under management jump 61% to $640M, launching new hedge fund and expanding product offerings.

Market News
01 Oct 2026, 14:30 WIB
PRNewsWire
View Source
Bullish
Valour's assets under management jump 61% to $640M, launching new hedge fund and expanding product offerings.

Valour, part of DeFi Technologies, reported a 61.2% increase in assets under management (AUM) to $640.2 million as of September 25, 2026, driven by strong investor inflows and trading activity. The company launched its first hedge fund, Smart Crypto Fund SP, and is developing additional fund structures and platforms to broaden its offerings. With a strong balance sheet and no debt, Valour aims to convert asset growth into higher revenue through management fees, staking income, and trading flow. The company also received an extension to meet Nasdaq's minimum bid price requirements, maintaining its listing while focusing on business growth and compliance.

DeFi Technologies' update on Valour's AUM growth is provided with Pluang market data as of Oct 01, 2026 16:51 WIB. For readers following US stocks on Pluang, 68 out of 150 stocks rose while 72 fell today. Notable movers include UMC at USD 25.11 with a 1-day change of +2.53%, BCS at USD 23.66 down -2.49%, and GOOG at USD 348.39 up +2.25%.

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
2 hours ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
2 hours ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
2 hours ago
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
Bullish
2 hours ago
Zcash (ZEC) price drops 3.57% in four hours with heavy long liquidations on Binance

Zcash (ZEC) price drops 3.57% in four hours with heavy long liquidations on Binance

Zcash (ZEC) fell 3.57% over four hours to $1,242 on Binance, with a 1.59% decline over 24 hours. During the same period, $840,000 in ZEC long positions were liquidated, far exceeding the $10,000 in short liquidations. This significant sell-off highli...

Market News
Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App